OTC Artificial Tears Market to Reach $7.22 Billion by 2033 Amid Rising Eye Disorders

Introduction

According to Renub Research Latest Report Over-the-Counter (OTC) Artificial Tears Market is poised for remarkable expansion over the coming decade, fueled by growing awareness of eye health and the increasing prevalence of dry eye syndrome. Valued at US$ 4.70 billion in 2024, the market is projected to reach US$ 7.22 billion by 2033, reflecting a compound annual growth rate (CAGR) of 4.88% from 2025 to 2033.

This surge comes as people across the globe grapple with the consequences of prolonged screen exposure, environmental pollutants, and aging—all of which contribute to ocular discomfort and dryness. Artificial tears, commonly known as lubricant eye drops, are now a vital part of daily routines, offering relief from irritation, allergies, and digital eye strain.

Market Overview

OTC artificial tears are designed to replicate and supplement natural tears, relieving dryness, irritation, and discomfort caused by insufficient tear production. Available in various formulations—such as solutions, gels, ointments, sprays, and emulsions—these products cater to different needs and preferences.

The market’s expansion is being driven by technological advancements, rising R&D investments, and consumer awareness about eye health. Manufacturers are focusing on developing preservative-free formulas, innovative packaging, and multifunctional products to address modern lifestyle demands.

One such example of innovation is Bausch & Lomb’s Alaway Preservative-Free Antihistamine Eye Drops, launched in 2021. As the first OTC antihistamine eye drop solution, it marked a milestone in non-prescription eye care by providing targeted relief for allergen-induced irritation without preservatives.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Sample Report

Key Growth Drivers

1. Aging Population and Rising Eye Disorders

The global population is aging rapidly, leading to a surge in age-related eye conditions such as dry eye syndrome, cataracts, and glaucoma. According to the United Nations, there were over 703 million people aged 65 and above in 2019, and this number continues to rise. Studies suggest that between 5% and 30% of seniors experience dry eye symptoms, which significantly boosts demand for artificial tears.

Elderly individuals often require ongoing eye care, and OTC artificial tears provide an affordable, accessible solution—particularly for mild to moderate cases that do not necessitate prescription treatments.

2. Increasing Screen Time and Digital Eye Strain

In today’s digital world, the widespread use of smartphones, computers, and tablets has resulted in increased incidences of digital eye strain. Extended screen exposure reduces blink frequency, leading to dryness and discomfort. With remote work and online education becoming the norm, artificial tear products have transitioned from being niche healthcare items to daily essentials.

3. Growing Incidence of Allergic Conjunctivitis and Dry Eye Syndrome

The prevalence of allergic conjunctivitis and dry eye syndrome has climbed sharply in recent years. Data from the American Academy of Ophthalmology (AAO) shows that 1.68 million men and 3.2 million women were diagnosed with dry eye syndrome in 2019. If left untreated, the condition can result in chronic irritation, blurred vision, and infection—driving patients to seek immediate OTC solutions.

4. Environmental and Lifestyle Factors

Environmental pollution, dust, smoke, and the extensive use of air conditioning have become key contributors to ocular discomfort. Urban dwellers, in particular, are more prone to dry eyes due to low humidity levels and constant exposure to airborne irritants. Artificial tears serve as a simple and effective defense mechanism, offering instant relief and moisture retention.

5. Technological and Product Innovations

Manufacturers are experimenting with biologic, recombinant, and small-molecule technologies to enhance product efficacy and safety. The emergence of preservative-free packaging systems and contact lens–compatible formulations has broadened the market’s appeal among consumers with sensitive eyes.

Market Challenges

Side Effects and Preservatives

While preservatives extend shelf life, they can also cause irritation or allergic reactions with prolonged use. As a result, consumers are shifting toward preservative-free formulations, which are gentler but more expensive to produce due to specialized packaging requirements. This increases retail prices, posing challenges for affordability in emerging markets.

Competition from Prescription Products

Prescription-only treatments, such as Restasis and Xiidra, continue to dominate the chronic dry eye therapy space. Their effectiveness in treating severe cases often diverts demand away from OTC alternatives. However, OTC artificial tears remain the go-to solution for mild to moderate conditions due to convenience and lower cost.

Segmentation Analysis

By Product Type:

Solutions dominate the market owing to their ease of use and versatility. They provide quick relief and are compatible with contact lenses, making them the preferred option among consumers.

Gels and Ointments are gaining traction for long-lasting moisture retention, particularly during nighttime use.

Spray Solutions and Emulsions appeal to users seeking innovative application methods.

By Application:

Dry Eye Syndrome remains the largest application segment, supported by rising awareness and diagnosis rates.

Allergies and Infections are also major contributors, as artificial tears help flush out irritants and reduce redness.

UV and Blue Light Protection formulations are emerging, catering to users exposed to excessive screen glare and sunlight.

By Distribution Channel:

Drugstores and Supermarkets lead global distribution, owing to widespread accessibility and consumer trust.

Online Pharmacies are growing rapidly as e-commerce transforms healthcare purchasing behavior.

Retail Pharmacies continue to be strong channels for personalized product recommendations.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Regional Insights

North America

North America dominates the OTC artificial tears market, driven by an aging population, increased screen exposure, and robust product availability. The United States leads with a strong retail presence across pharmacies and supermarkets, while online sales are accelerating due to subscription-based models.

According to the Centers for Disease Control and Prevention (CDC), over 4.2 million Americans aged 40 and older suffer from low vision or blindness, primarily caused by cataracts and glaucoma—further supporting market demand.

Europe

The United Kingdom, Germany, and France represent key European markets. Rising cases of dry eye syndrome among urban professionals and the elderly, coupled with environmental challenges like air pollution, are driving growth. Consumer preference for preservative-free and organic products is shaping market innovation in the region.

Asia-Pacific

The Asia-Pacific region, led by China, India, and Japan, is expected to record the fastest growth. Rapid urbanization, digital device dependency, and environmental pollution have created an ideal environment for market expansion. In India, urban populations are increasingly turning to OTC eye gels to counteract dryness caused by screen time and air-conditioned environments.

Middle East and Africa

Countries such as Saudi Arabia and the UAE face unique challenges, including dry climates and frequent dust exposure. These environmental stressors have fueled demand for artificial tears, particularly preservative-free variants. Rising healthcare awareness and easy access to retail pharmacies support steady market growth in the region.

Competitive Landscape

The OTC artificial tears market is moderately consolidated, with several global players introducing innovative formulations and expanding distribution networks. Key companies include:

AbbVie Inc.

Akorn Inc.

Alcon

Bausch Health Companies Inc.

Johnson & Johnson

Nicox S.A.

Novartis AG

Santen Pharmaceutical Co. Ltd.

Sun Pharmaceutical Industries Ltd.

These companies focus on product differentiation through advanced R&D, sustainable packaging, and digital marketing strategies. Strategic collaborations and acquisitions are also becoming common to expand product portfolios and market reach.

Future Outlook

The future of the OTC artificial tears market looks bright as global consumers prioritize eye health. The combination of aging demographics, increased digital exposure, and environmental stress will continue to drive demand. The market’s shift toward preservative-free, natural, and multi-benefit formulations reflects an evolving preference for safer and more holistic eye care.

As innovations in ophthalmic technology progress, manufacturers that emphasize comfort, convenience, and sustainability will lead the way. With steady growth projected through 2033, the OTC artificial tears market remains one of the most promising sectors in consumer healthcare.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.